These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 1906004

  • 1. Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.
    Bench CJ, Price GW, Lammertsma AA, Cremer JC, Luthra SK, Turton D, Dolan RJ, Kettler R, Dingemanse J, Da Prada M.
    Eur J Clin Pharmacol; 1991; 40(2):169-73. PubMed ID: 1906004
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.
    Fowler JS, Volkow ND, Logan J, Schlyer DJ, MacGregor RR, Wang GJ, Wolf AP, Pappas N, Alexoff D, Shea C.
    Neurology; 1993 Oct; 43(10):1984-92. PubMed ID: 8413955
    [Abstract] [Full Text] [Related]

  • 4. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
    Hirvonen J, Kailajärvi M, Haltia T, Koskimies S, Någren K, Virsu P, Oikonen V, Sipilä H, Ruokoniemi P, Virtanen K, Scheinin M, Rinne JO.
    Clin Pharmacol Ther; 2009 May; 85(5):506-12. PubMed ID: 19129751
    [Abstract] [Full Text] [Related]

  • 5. Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain.
    Logan J, Fowler JS, Volkow ND, Wang GJ, MacGregor RR, Shea C.
    Nucl Med Biol; 2000 Jan; 27(1):43-9. PubMed ID: 10755644
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. PET imaging of monoamine oxidase B in peripheral organs in humans.
    Fowler JS, Logan J, Wang GJ, Volkow ND, Zhu W, Franceschi D, Pappas N, Ferrieri R, Shea C, Garza V, Xu Y, MacGregor RR, Schlyer D, Gatley SJ, Ding YS, Alexoff D.
    J Nucl Med; 2002 Oct; 43(10):1331-8. PubMed ID: 12368371
    [Abstract] [Full Text] [Related]

  • 8. [3H]Ro 19-6327: a reversible ligand and affinity labelling probe for monoamine oxidase-B.
    Cesura AM, Galva MD, Imhof R, Kyburz E, Picotti GB, Da Prada M.
    Eur J Pharmacol; 1989 Mar 29; 162(3):457-65. PubMed ID: 2744079
    [Abstract] [Full Text] [Related]

  • 9. [3H]Ro 16-6491, a selective probe for affinity labelling of monoamine oxidase type B in human brain and platelet membranes.
    Cesura AM, Imhof R, Takacs B, Galva MD, Picotti GB, Da Prada M.
    J Neurochem; 1988 Apr 29; 50(4):1037-43. PubMed ID: 3126263
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Bondiolotti GP, Galva MD, Villa F, Sciaba L, Picotti GB.
    Biochem Pharmacol; 1995 Jun 29; 50(1):97-102. PubMed ID: 7605351
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET.
    Freedman NM, Mishani E, Krausz Y, Weininger J, Lester H, Blaugrund E, Ehrlich D, Chisin R.
    J Nucl Med; 2005 Oct 29; 46(10):1618-24. PubMed ID: 16204711
    [Abstract] [Full Text] [Related]

  • 14. An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo.
    Fowler JS, Volkow ND, Logan J, Pappas N, King P, MacGregor R, Shea C, Garza V, Gatley SJ.
    Life Sci; 1998 Oct 29; 63(2):PL19-23. PubMed ID: 9674950
    [Abstract] [Full Text] [Related]

  • 15. Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography.
    Gulyás B, Pavlova E, Kása P, Gulya K, Bakota L, Várszegi S, Keller E, Horváth MC, Nag S, Hermecz I, Magyar K, Halldin C.
    Neurochem Int; 2011 Jan 29; 58(1):60-8. PubMed ID: 21075154
    [Abstract] [Full Text] [Related]

  • 16. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
    Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P.
    Alzheimers Res Ther; 2017 Mar 31; 9(1):25. PubMed ID: 28359327
    [Abstract] [Full Text] [Related]

  • 17. Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET.
    Fowler JS, MacGregor RR, Wolf AP, Arnett CD, Dewey SL, Schlyer D, Christman D, Logan J, Smith M, Sachs H.
    Science; 1987 Jan 23; 235(4787):481-5. PubMed ID: 3099392
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of platelet monoamine oxidase type B by selegiline.
    Heinonen EH, Anttila MI, Nyman LM, Pyykkö KA, Vuorinen JA, Lammintausta RA.
    J Clin Pharmacol; 1997 Jul 23; 37(7):597-601. PubMed ID: 9243352
    [Abstract] [Full Text] [Related]

  • 19. Monoamine oxidase B single-photon emission tomography with [123I]Ro 43-0463: imaging in volunteers and patients with temporal lobe epilepsy.
    Buck A, Frey LD, Bläuenstein P, Krämer G, Siegel A, Weber B, Schubiger PA, Wieser HG.
    Eur J Nucl Med; 1998 May 23; 25(5):464-70. PubMed ID: 9575241
    [Abstract] [Full Text] [Related]

  • 20. Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.
    Fowler JS, Logan J, Volkow ND, Shumay E, McCall-Perez F, Jayne M, Wang GJ, Alexoff DL, Apelskog-Torres K, Hubbard B, Carter P, King P, Fahn S, Gilmor M, Telang F, Shea C, Xu Y, Muench L.
    Neuropsychopharmacology; 2015 Feb 23; 40(3):650-7. PubMed ID: 25249059
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.